medigraphic.com
ISSN 1560-4381 (Print)

2015, Number 1

<< Back Next >>

Correo Científico Médico 2015; 19 (1)

Coagulation disorders in chronic liver disease

Rodríguez DM, Mulet PA, Pérez BAM, Miranda MZ, Pérez PA

Language: Spanish
References: 44
Page: 98-118
PDF size: 495.91 Kb.


ABSTRACT

Normal haemostasis performs based on a complex balance between procoagulant, anticoagulant mechanisms and the fibrinolytic system, in which the liver exerts an important role. A review was performed aimed at examining aspects in relation with the hemostatic alterations in patients with chronic liver disease. A bibliographical review was done to accomplish that purpose in Pubmed, EBSCO, Medline, and Hinari database. Platelet quantitative and qualitative abnormalities and diminished synthesis of clotting factors were approached, as well as dysfibrinogenemia, fibrinolysis disorders, vitamin K deficiency, and a state compatible with disseminated intravascular coagulation. The following conclusions were made: the hemostatic disorders in the patient with cirrhosis are related to an advanced state of the disease, with clinical consequences which are in a wide spectrum from bleeding tendency to thrombosis, and that the standard coagulation tests do not appropriately reflect these phenomena. Nevertheless, recent advances in analytical techniques for the diagnosis of these abnormalities constitute promising tools for their proper identification in the clinical context.


REFERENCES

  1. Colina AJ, Carballo TT, Torres IW. Hemostasia normal. En: Suardíaz JH, Cruz CL, Colina A. Laboratorio Clínico. La Habana: Editorial Ciencias Médicas; 2004.p.309-321.

  2. 2.Wallach J. Interpretación clínica de las pruebas de laboratorio. 4ª ed. La Habana: Editorial Ciencias Médicas; 2006.

  3. Northup PG. Hypercoagulation in liver disease. Clin Liver Dis. 2009[citado 5 abr 2014];31(1):109-116. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150315

  4. Alkim H, Ayaz S, Sasmaz N, Oguz P, Sahin B. Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis. Clin Appl Thromb Hemost. 2012 [citado 10 abr 2014]; 18(4):409-415. Disponible en: http://cat.sagepub.com/content/18/4/409.full.pdf+html

  5. Monroe DM, Maureane H. The coagulation cascade in cirrhosis. Clin Liver Dis. 2009 [citado 10 abr 2014];13(1):1-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150304

  6. Lisman T, Leebeek FWG. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007[citado 10 abr 2014]; 24,(4):250-258. Disponible en: http://www.karger.com/Article/Pdf/103655

  7. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010[citado 8 abr 2014]; 116(6): 878-885. Disponible en: http://bloodjournal.hematologylibrary.org/content/116/6/878.full.pdf+html

  8. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal convencional coagulation tests. Hepatology. 2005 [citado 10 abr 2014]; 41(3):553-558. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/hep.20569/pdf

  9. Mackavey CL, Hanks R. Hemostasis, coagulation abnormalities, and liver disease. Crit Care Nurs Clin N Am. 2013 [citado 15 abr 2014];25(4):435-446. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24267280

  10. Yang ZJ, Costa KA, Novelli EM, Smith RE. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost. 2014[citado 15 abr 2014];20(2):169-178. Disponible en: http://cat.sagepub.com/content/20/2/169.full.pdf+html

  11. Menéndez Alonso E, Rubio Arias S, Sánchez Calvin MT. Visión moderna de la hemostasia: nuevo modelo de coagulación. En: Curso de formación a distancia Nº2. Madrid: Asociación Española de Biopatología Médica; 2011.p. 584-611. Disponible en: http://aebm.org/formacion%20distancia/distancia%202011-2012/Taller/MONOGRAFIAS%202011/2.-%20HEMOSTASIA.pdf

  12. Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis. 2009 [citado 16 abr 2014]; 13(1):21-31. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150306

  13. Aristizábal Henao N, Madrid Muñoz CA, Restrepo Gutiérrez JC. Hepatopatía crónica: sangrado versus trombosis. Rev Col Gastroenterol.2011 [citado 18 abr 2014]; 26 (4): 285-291. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572011000400008

  14. Téllez Ávila FI, Chávez Tapia NC, Torre Delgadillo A. Trastornos de coagulación en el cirrótico. Rev invest Clín.2007 [citado 19 abr 2014]; 59(2). Disponible en: http://www.scielo.org.mx/pdf/ric/v59n2/v59n2a10.pdf

  15. Ng VL. Liver disease, coagulation testing and hemostasis. Clin Lab Med. 2009 [citado 23 abr 2014]; 29(2):265–282. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19665678

  16. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrosis. Aliment Pharmacol Ther. 2010 [citado 25 abr 2014]; 31:366-374. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04182.x/pdf

  17. Saavedra González JA, Ovadía Cardona LM, Muñoz Maya OG, Correa Arango G. Alteraciones de la coagulación en cirrosis, viejos y nuevos paradigmas. Rev Col Gastroenterol. 2012. [citado 5 may 2014]; 27(2): 104-111. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572012000200008

  18. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease. 9th Ed. Philadelphia: Elsevier; 2010.

  19. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med. 2010 [citado 7 may 2014]; 5(1):7-12. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19714443

  20. Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol. 2011 [citado 7 may 2014]; 55(6):1415-1427. Disponible en: http://www.sciencedirect.com/science/article/pii/S0168827811004995

  21. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology.4 ed. Germany: Flying Publisher; 2014.[citado 7 may 2014]Disponible en: http://www.flyingpublisher.com/9004.php

  22. Lisman T, Bongers T, Adelmeijer J, Janssen HLA, de Maat MPM, de Groot PG. Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatol.2006 [citado 10 may 2014]; 44:53-61. Disponible en: http://onlinelibrary.wiley.com/enhanced/doi/10.1002/hep.21231/

  23. Zhang DL, Hao JY, Yang N. Value of D-dimer and protein S for diagnosis of portal vein thrombosis in patients with liver cirrhosis. J Int Medic Res. 2013 [citado 10 may 2014];41(3): 664-672. Disponible en: http://imr.sagepub.com/content/41/3/664.full.pdf+html

  24. Smalberg JH, Leebeek FWG. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis. 2009 [citado 12 may 2014];13(1):33-42. Disponible en:

  25. http://www.ncbi.nlm.nih.gov/pubmed/?term=Superimposed+Coagulopathic+Conditions+in+Cirrhosis%3A+Infection+and+Endogenous+Heparinoids%2C+Renal+Failure%2C+and+Endothelial+Dysfunction

  26. Zambruni A, Thalheimer U, Coppell J, Riddell A, Mancuso A, Leandro G, et al. Endogenous Heparin-like Activity Detected by Anti-Xa Assay in Infected Cirrhotic and Non-Cirrhotic Patients. Scand J Gastroenterol.2004 [citado 12 may 2014]39(9):830-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Endogenous+Heparin-like+Activity+Detected+by+Anti-Xa+Assay+in+Infected+Cirrhotic+and+Non-Cirrhotic+Patients

  27. Kalambokis G, Tsianos EV. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts? Med Hypotheses.2011 [citado 12 may 2014]; 76(1):105-109. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Endotoxaemia+in+the+pathogenesis+of+cytopenias+in+liver+cirrhosis.+Could+oral+antibiotics+raise+blood+counts%3F+Med+Hypotheses

  28. Shah NL, Caldwell SH, Berg CL. The Role of Anti-fibrinolytics, rFVIIa and other pro-Coagulants: prophylactic versus rescue? Clin Liver Dis.2009 [citado 12 may2014];13:87-93. Disponible en: http://download.journals.elsevierhealth.com/pdfs/journals/1089-3261/PIIS1089326108000949.pdf

  29. Aldawood A, Arabi Y, Aljumah A, Alsaeedi A, Rishu A, Aldorzi H, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J.2011 [citado 12 may 2014];9:1. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033790/

  30. Saleh T, Matta F, Alali F, Stein PD. Venous thromboembolism with chronic liver disease. Am J Med.2011 [citado 12 may 2014]; 124(1):64-68. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21187186

  31. Al-Dorzi HM, Tamim HM, Aldawood AS, Arabi YM. Venous Thromboembolism in critically ill cirrhotic patients: practices of prophylaxis and incidence. Thromb. 2013 [citado 12 may 2014]; 2013 :1-7; Disponible en: http://downloads.hindawi.com/journals/thrombosis/2013/807526.pdf

  32. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a Nationwide US study. Clin Gastroenterol Hepatol. 2010 [citado 12 may 2014]; 8:800-805. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Liver+cirrhosis+is+associated+with+venous+thromboembolism+among+hospitalized+patients+in+a+Nationwide+US+study

  33. García Pagan JC, Valla DC. Portal vein thrombosis: A predictable milestone in cirrhosis? J Hepatol. 2009 [citado 15 may 2014]; 51(4):632–634. Disponible en: http://ac.els-cdn.com/S0168827809004449/1-s2.0-S0168827809004449-main.pdf?_tid=79af656c-bc22-11e3-8019-00000aab0f26&acdnat=1396634380_c4ad7b75704c5c4659dba0356561ba5d

  34. Anstee Q, Wright M, Glodin R, Thursz MR. Parenchymal Extinction: Coagulation and Hepatic Fibrogenesis. Clin Liver Dis. 2009 [citado 8 abr 2014];13(1):117–126. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150316

  35. Caldwell SH, Sanyal AJ. Coagulation disorders and bleeding in liver disease: future directions. Clin Liver Dis. 2009 [citado 15 may 2014];13:155-157. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Coagulation+disorders+and+bleeding+in+liver+disease%3A+future+directions

  36. Tripodi A. Tests of coagulation in liver disease. Clin Liver Dis. 2009 [citado 15 may 2014];13:55-61. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150309

  37. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000 [citado 15 may 2014]; 46(12): 2027–2049. Disponible en: http://www.clinchem.org/content/46/12/2027.full.pdf+html

  38. Mulet Batista D, Ramírez Pérez C, Abreu Sera G, Pérez Mir J, Pérez González JA. Coeficiente internacional normalizado, útil herramienta en la terapia anticoagulante oral. Medisur. 2012 [citado 15 may 2014]; 10(3): 184-187. Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/1778

  39. Kamath PS, Kim WR. The international normalized ratio of prothrombin time in the Model for End-Stage Liver Disease Score: A reliable measure. Clin Liver Dis.2009 [citado 16 may 2014];13(1):63-66. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150310

  40. Arjal R, Trotter JF. International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis. 2009 [citado 16 may 2014];13(1):67-71. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150311

  41. Argo CK, Balogun RA. Blood Products, Volume control, and renal support in the coagulopath in liver disease. Clin Liver Dis. 2009 [citado 16 may 2014];13:73-85. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Blood+Products%2C+Volume+control%2C+and+renal+support+in+the+coagulopath+in+liver+disease.

  42. Hugenholtz GC, Porte RG, Lisman T. The platelet and platelet function testing in liver disease. Clin Liver Dis. 2009 [citado 16 may 2014]; 13(1):11–20. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19150305

  43. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-γ-Carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular Carcinoma. Gastroenterol. 2010 [citado 16 may 2014]; 138(2):493-502. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19852963

  44. Sherman M. Serological surveillance for hepatocellular carcinoma: Time to quit. J Hepatol 2010 [citado 16 may 2014]; 52:614-615. Disponible en: http://ac.els-cdn.com/S0168827810000036/1-s2.0-S0168827810000036-main.pdf?_tid=3aa26ba2-bc28-11e3-bbf7-00000aacb35e&acdnat=1396636852_40bc3bd0318fd687577eb7eb5310b11b




2020     |     www.medigraphic.com